At A Glance
1
Synairgen plc discovers and develops drugs for respiratory diseases.
2
No significant events in the past 90 days.
—
Market Cap
—
Revenue
—
Net Income
Employees36
Fundamentals
How The Business Makes Money
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
Industry Biotechnology
Activity
What Changed Recently
No significant events in the past 90 days.
Analyst View
Company Profile
CIKUNKNOWN_SYGGF
ISINGB00B0381Z20
Phone44 23 8051 2800
AddressMailpoint 810, Southampton, SO16 6YD, GB
SEC EDGAR